(Q36830134)

16 August 2017

1 reference

title

Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics (English)

1 reference

16 August 2017

Pierre Chue

1

1 reference

16 August 2017

Robin Emsley

series ordinal

2

1 reference

16 August 2017

publication date

1 January 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

21

1 reference

16 August 2017

issue

6

1 reference

16 August 2017

page(s)

441-448

1 reference

https://scigraph.springernature.com/pub.10.2165/00023210-200721060-00001

16 August 2017

exact match

0 references

cites work

Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00023210-200721060-00001

Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic

21 January 2018

1 reference

12 December 2020

Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone

1 reference

12 December 2020

Clinical guidelines: Dosing and switching strategies for long-acting risperidone.

1 reference

12 December 2020

Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies

1 reference

12 December 2020

Depot antipsychotic drugs. Place in therapy

1 reference

12 December 2020

Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study

1 reference

12 December 2020

Systematic review of patient and nurse attitudes to depot antipsychotic medication.

1 reference

12 December 2020

Risks versus benefits of different types of long-acting injectable antipsychotics.

1 reference

12 December 2020

Time course for antipsychotic treatment response in first-episode schizophrenia

1 reference

12 December 2020

Risperidone long-acting injection

1 reference

12 December 2020

Management of first episode psychotic illness in Afro-Caribbean patients

1 reference

12 December 2020

Guidelines for depot antipsychotic treatment in schizophrenia

1 reference

12 December 2020

Sustained drug delivery optimizes long-term treatment of patients with schizophrenia

1 reference

12 December 2020

Long-acting risperidone: a review of its use in schizophrenia

1 reference

12 December 2020

Long-acting risperidone injection.

1 reference

12 December 2020

Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients

1 reference

12 December 2020

Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone

1 reference

12 December 2020

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders

1 reference

12 December 2020

Relapse and rehospitalization: comparing oral and depot antipsychotics.

1 reference

12 December 2020

Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration

1 reference

12 December 2020

New generation antipsychotics for first episode schizophrenia

1 reference

12 December 2020

Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year

1 reference

12 December 2020

Emerging psychosis in young people - Part 3 - key issues for prolonged recovery.

1 reference

12 December 2020

Strategies for increasing treatment compliance: the role of long-acting antipsychotics

1 reference

12 December 2020

Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study

1 reference

12 December 2020

Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system

1 reference

12 December 2020

Long-acting injectable risperidone

1 reference

12 December 2020

Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial

1 reference

12 December 2020

The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.

1 reference

12 December 2020

Antipsychotic depot medication and attitudes of community psychiatric nurses.

1 reference

12 December 2020

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol

1 reference

12 December 2020

Clinical practice guidelines. Treatment of schizophrenia.

1 reference

12 December 2020

Pharmacotherapy of first-episode psychosis

1 reference

12 December 2020

Clinical effectiveness in first-episode patients.

1 reference

12 December 2020

On the path to recovery: patients' experiences of treatment with long-acting injections of antipsychotic medication

1 reference

12 December 2020

First-episode schizophrenia: a focus on pharmacological treatment and safety considerations

1 reference

12 December 2020

Risperidone long-acting injection: a brief overview

1 reference

12 December 2020

Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia.

1 reference

12 December 2020

Pharmacological treatments for first-episode schizophrenia

1 reference

12 December 2020

An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia

1 reference

12 December 2020

Long-acting injectable antipsychotics in the elderly: guidelines for effective use.

1 reference

12 December 2020

Pharmacological management of first-episode schizophrenia and related nonaffective psychoses

1 reference

12 December 2020

Clinical review of a long-acting, injectable formulation of risperidone

1 reference

12 December 2020

The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia

1 reference

12 December 2020

Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics

1 reference

12 December 2020

Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic

1 reference

12 December 2020

Insight in first-episode psychosis.

1 reference

12 December 2020

Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables

1 reference

12 December 2020

Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable

1 reference

12 December 2020

Psychiatrists' attitudes to maintenance medication for patients with schizophrenia

1 reference

12 December 2020

Fluphenazine vs Placebo in Patients With Remitted, Acute First-Episode Schizophrenia

1 reference

12 December 2020

Antipsychotic agents. Gradually improving treatment from the traditional oral neuroleptics to the first atypical depot

1 reference

12 December 2020

1 reference

12 December 2020

Intramuscular preparations of antipsychotics: uses and relevance in clinical practice

1 reference

12 December 2020

Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder.

1 reference

12 December 2020

A systematic review of longitudinal outcome studies of first-episode psychosis

1 reference

12 December 2020

Adherence assessments and the use of depot antipsychotics in patients with schizophrenia

1 reference

12 December 2020

Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies

1 reference

12 December 2020

Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone

1 reference

12 December 2020

Compliance and convenience: do physicians and patients see depot medication differently?

1 reference

12 December 2020

A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia

1 reference

12 December 2020

Choice of maintenance medication for schizophrenia

1 reference

12 December 2020

The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia

1 reference

12 December 2020

Selecting patients for long-acting novel antipsychotic therapy

1 reference

12 December 2020

Long-acting injectable risperidone: an emerging tool in schizophrenia treatment

1 reference

12 December 2020

Clinical experience and management considerations with long-acting risperidone

1 reference

12 December 2020

The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update

1 reference

12 December 2020

10.2165/00023210-200721060-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

16 August 2017

1040036231

0 references

1 reference